| Project/Area Number |
24590655
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
KANAI MASASHI 京都大学, 医学(系)研究科(研究院), 講師 (70432416)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
村上 善基 大阪市立大学, 医学系研究科, 准教授 (00397556)
金井 恵理 天理医療大学, 教授 (20372584)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | クルクミン / がん / マイクロRNA / QOL / miRNA / 膵癌 / 抗がん薬 |
|---|
| Outline of Final Research Achievements |
Many preclinical studies have demonstrated the anti-cancer effect of curcumin and curcumin could be a promising anti-cancer drug with minimal side effects. On the other hand, poor bioavailability has been a major challenge in developing curcumin as an anti-cancer drug. To overcome this problem, a highly bioavailable curcumin has been developed. First, we tested the safety of this new form of curcumin in cancer patients and verified its improved bioavailability as well as its safety. Then, we proceeded to a randomized placebo-controlled clinical trial to demonstrate its efficacy. To date, we have observed the improvement of quality of life or increase of miRNA involved in tumor suppression after curcumin administration. We are now trying to verify these findings in a larger cohort and our final goal is to introduce curcumin into daily clinical practice to treat patients with cancer.
|
